Condensed Consolidated Statements of Changes in Equity (Statement) - USD ($) $ in Thousands		Total		IPO	Common Units		Common Stock	Common Stock IPO	Additional Paid in Capital	Additional Paid in Capital IPO	Accumulated Other Comprehensive Income (Loss)	Retained Earnings	Noncontrolling Interests
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2021		$ 13,660
Increase (Decrease) in Temporary Equity [Roll Forward]
Net income attributable to redeemable noncontrolling interests		4,674
Distributions to redeemable noncontrolling interests		(7,538)
Redeemable noncontrolling interests, ending balance at Dec. 31, 2022		10,796
Balance, beginning of period (in shares) at Dec. 31, 2021					481,331,862	[1]	0
Balance, beginning of period at Dec. 31, 2021		978,345			$ 510,357		$ 0		$ 0		$ (9,968)	$ 87,451	$ 390,505
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to Ardent Health Partners, Inc.		188,909										188,909
Net income attributable to noncontrolling interests		71,788											71,788
Other comprehensive income (loss)		36,501									36,501
Distributions to noncontrolling interests		(61,833)											(61,833)
Distributions to common unit holders		(174,811)										(174,811)
Vesting of Class C Units (in shares)	[1]				1,394,682
Vesting of Class C Units		611			$ 611
Balance, ending of period (in shares) at Dec. 31, 2022					482,726,544	[1]	0
Balance, ending of period at Dec. 31, 2022		1,039,510			$ 510,968		$ 0		0		26,533	101,549	400,460
Increase (Decrease) in Temporary Equity [Roll Forward]
Net income attributable to redeemable noncontrolling interests		(3,494)
Redeemable noncontrolling interests, ending balance at Dec. 31, 2023		7,302
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to Ardent Health Partners, Inc.		53,904										53,904
Net income attributable to noncontrolling interests		78,567											78,567
Other comprehensive income (loss)		(7,972)									(7,972)
Distributions to noncontrolling interests		(63,875)											(63,875)
Vesting of Class C Units (in shares)	[1]				2,196,284
Vesting of Class C Units		$ 904			$ 904
Redemption of equity attributable to noncontrolling interests					$ 14,990
Balance, ending of period (in shares) at Dec. 31, 2023		0			484,922,828	[1]	0
Balance, ending of period at Dec. 31, 2023		$ 1,075,014	[2]		$ 496,882		$ 0		0		18,561	155,453	404,118
Increase (Decrease) in Temporary Equity [Roll Forward]
Net income attributable to redeemable noncontrolling interests		(6,144)
Redeemable noncontrolling interests, ending balance at Dec. 31, 2024		1,158
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to Ardent Health Partners, Inc.		210,343										210,343
Net income attributable to noncontrolling interests		95,509											95,509
Other comprehensive income (loss)		(8,824)									(8,824)
Distributions to noncontrolling interests		(72,856)											(72,856)
Vesting of Class C Units (in shares)					986,855	[1]		13,800,000
Vesting of Class C Units		738		$ 198,792	$ 738			$ 138		$ 198,654
Redemption of equity attributable to noncontrolling interests		26,024											11,034
Conversion of member units to common stock (in shares)					(485,909,683)	[1]	(128,963,328)
Conversion of member units to common stock		0			$ (497,620)		$ 1,290		536,291				(39,961)
Proceeds from the sale of noncontrolling interest		5,364							2,351				3,013
Vesting of restricted stock unit awards (in shares)							32,227
Tax withholding on vesting of restricted stock unit awards (in shares)							(8,200)
Tax withholding on vesting of restricted stock unit awards		(121)							(121)
Forfeiture of restricted stock awards (in shares)							(39,537)
Equity-based compensation		$ 17,240							17,240
Balance, ending of period (in shares) at Dec. 31, 2024		142,747,818			0		142,747,818
Balance, ending of period at Dec. 31, 2024		$ 1,521,199	[2]		$ 0		$ 1,428		$ 754,415		$ 9,737	$ 365,796	$ 389,823

[1] (*) See Note 1 "Description of the Business and Basis of Presentation - Initial Public Offering and Corporate Conversion" for further discussion.

[2] As of December 31, 2024 and December 31, 2023, the consolidated balance sheets included total liabilities of consolidated variable interest entities of $306.4 million and $337.8 million, respectively. Refer to Note 2 "Summary of Significant Accounting Policies" for further discussion.